CompletedNot applicableNCT02043379
Post-bypass Prophylactic IVIG in Infants and Neonates
Studying OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Jeffrey Alten, MDUniversity of Alabama at Birmingham Pediatric Cardiac Critical Care
- Intervention
- IVIG(drug)
- Enrollment
- 50 enrolled
- Eligibility
- All sexes
- Timeline
- 2014 – 2015
Study locations (1)
- Children's of Alabama, Birmingham, Alabama, United States
Collaborators
Grifols Biologicals, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02043379 on ClinicalTrials.govOther trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05645107A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaGrifols Therapeutics LLC
- RECRUITINGPHASE2, PHASE3NCT05678621Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or ExtensionMonash University
- RECRUITINGNCT00001244Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)National Institute of Allergy and Infectious Diseases (NIAID)
See all trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects →